Co-Diagnostics (id:5835 CODX)
1.05 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/21/2024 6:52:23 PM)
Exchange closed, opens in 14 hours 37 minutes
About Co-Diagnostics
Market Capitalization 33.21M
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
| Headquarters (address) |
2401 South Foothill Drive Salt Lake City 84109 UT United States |
| Phone | (801) 438-1036 |
| Website | https://www.codiagnostics.com |
| Employees | 155 |
| Sector | Healthcare |
| Industry | Medical Devices |
| Ticker | CODX |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.00 - 2.23 |
| Market Capitalization | 33.21M |
| P/E trailing | -0.867 |
| P/E forward | -0.889 |
| Price/Sale | 4.54 |
| Price/Book | 0.521 |
| Beta | -0.846 |
| EPS | -1.38 |
| EPS United States (ID:6, base:3395) | 24.30 |